Chief Financial Officer

Senior Vice President CMC Development

Alnylam price target raised by $54 at Stifel, here's why

Alnylam begins global Phase 3 trial dosing of zilebesiran

Cambridge-based Alnylam Pharmaceuticals pulls TV ad after Trump crackdown on drug industry spots

Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing

Business Account Executive

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, committed to transforming the lives of people with rare and common diseases. They are seeking an experienced Business Account Executive to promote AMVUTTRA™ and enhance market knowledge of hATTR amyloidosis by targeting healthcare providers and developing strategic account plans.

Business Account Executive, TTR - Milwaukee, WI

Associate Director - Business Account Executive (Rare Disease)

Business Account Executive Rare Disease

Business Account Executive-Ultra Rare Disease- PH1- Neph/Uro/Ped. Neph/Ped. Ur/AHP-Hem/Oncs/Gastros 

Business Account Executive - Rare Diseases (PH1 & AHP)

Sign up with Google

Sign in with Google